Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 11, Number 3—March 2005
Dispatch

Inquilinus limosus in Patients with Cystic Fibrosis, Germany

Nele Wellinghausen*Comments to Author , Andreas Essig*, and Olaf Sommerburg*
Author affiliations: *University of Ulm, Ulm, Germany

Main Article

Table

Antimicrobial susceptibility of Inquilinus limosus strains

Antimicrobial agent MIC (µg/mL)
Isolate A-1 Isolate A-2 Isolate A-3 Isolate B LMG 20952T
Trimethoprim/sulfamethoxazole >32 >32 >32 >32 >32
Amikacin 8 32 32 >256 >256
Gentamicin 8 16 12 >256 12
Tobramycin >256 >256 >256 >256 >256
Ampicillin >256 >256 >256 >256 >256
Piperacillin/tazobactam >256 >256 >256 >256 >256
Cefotaxime >32 >32 >32 >32 >32
Ceftazidime 4 4 4 0.5 32
Imipenem 0.012 0.012 0.016 0.006 0.016
Ciprofloxacin 0.032 0.032 0.032 0.500 0.064
Colistin* Resistant Resistant Resistant Resistant Resistant

*Susceptibility testing done by disk diffusion (see text); no zone of inhibition was seen.

Main Article

Page created: April 25, 2012
Page updated: April 25, 2012
Page reviewed: April 25, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external